HK1222559A1 - 使用貝那利珠單抗增加哮喘患者用力呼氣量的方法 - Google Patents

使用貝那利珠單抗增加哮喘患者用力呼氣量的方法 Download PDF

Info

Publication number
HK1222559A1
HK1222559A1 HK16110776.1A HK16110776A HK1222559A1 HK 1222559 A1 HK1222559 A1 HK 1222559A1 HK 16110776 A HK16110776 A HK 16110776A HK 1222559 A1 HK1222559 A1 HK 1222559A1
Authority
HK
Hong Kong
Prior art keywords
benralizumab
antigen
binding fragment
weeks
patient
Prior art date
Application number
HK16110776.1A
Other languages
English (en)
Chinese (zh)
Inventor
‧沃德
C‧沃德
‧羅斯科斯
L‧罗斯科斯
王冰
‧雷布爾
D‧雷布尔
Original Assignee
米迪缪尼有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 米迪缪尼有限公司 filed Critical 米迪缪尼有限公司
Publication of HK1222559A1 publication Critical patent/HK1222559A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Endocrinology (AREA)
HK16110776.1A 2013-08-12 2014-08-07 使用貝那利珠單抗增加哮喘患者用力呼氣量的方法 HK1222559A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361864948P 2013-08-12 2013-08-12
US61/864,948 2013-08-12
PCT/US2014/050119 WO2015023507A2 (en) 2013-08-12 2014-08-07 Methods for increasing forced expiratory volume in asthmatics using benralizumab

Related Child Applications (1)

Application Number Title Priority Date Filing Date
HK42021024819.1A Addition HK40035227A (en) 2013-08-12 2016-09-12 Methods for increasing forced expiratory volume in asthmatics using benralizumab

Publications (1)

Publication Number Publication Date
HK1222559A1 true HK1222559A1 (zh) 2017-07-07

Family

ID=52448838

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16110776.1A HK1222559A1 (zh) 2013-08-12 2014-08-07 使用貝那利珠單抗增加哮喘患者用力呼氣量的方法

Country Status (26)

Country Link
US (1) US9441046B2 (https=)
EP (5) EP3033104B1 (https=)
JP (4) JP6746496B2 (https=)
KR (1) KR102337599B1 (https=)
CN (2) CN105451769A (https=)
AU (2) AU2014306959B2 (https=)
BR (1) BR112016002317A8 (https=)
CA (1) CA2917603C (https=)
CY (2) CY1122033T1 (https=)
DK (2) DK3033104T3 (https=)
ES (2) ES2866426T3 (https=)
HK (1) HK1222559A1 (https=)
HR (2) HRP20190920T1 (https=)
HU (2) HUE043497T2 (https=)
LT (2) LT3520811T (https=)
ME (1) ME03403B (https=)
MX (2) MX381102B (https=)
PL (2) PL3520811T3 (https=)
PT (2) PT3520811T (https=)
RS (2) RS58711B1 (https=)
RU (1) RU2703568C2 (https=)
SG (1) SG11201600483QA (https=)
SI (2) SI3033104T1 (https=)
SM (2) SMT201900311T1 (https=)
TR (1) TR201907907T4 (https=)
WO (1) WO2015023507A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2918105C (en) * 2013-08-12 2023-02-28 Medimmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab
CN111617244A (zh) * 2013-08-12 2020-09-04 阿斯特拉捷利康股份公司 使用贝那利珠单抗改善哮喘症状的方法
KR20160061352A (ko) * 2013-10-15 2016-05-31 메디뮨 엘엘씨 벤랄리주맙을 사용하여 만성 폐쇄성 폐 질환을 치료하는 방법
SI3060229T1 (sl) 2013-10-24 2021-11-30 Astrazeneca Ab Stabilne vodne formulacije protiteles
TW202110479A (zh) * 2019-05-16 2021-03-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法
TW202126688A (zh) * 2019-09-27 2021-07-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療遲發性氣喘之方法
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法
WO2026053166A1 (en) * 2024-09-06 2026-03-12 Medimmune Limited Anti-il5r-alpha treatment for acute exacerbations of asthma and copd

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241944C (zh) 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7404953B2 (en) 2000-02-15 2008-07-29 Kyowa Hakko Kogyo Co., Ltd. Methods using eosinophil-specific apoptosis inducer
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
AU2004279740A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Antibody composition specifically binding to IL-5 receptor
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
HUE036885T2 (hu) 2007-05-14 2018-08-28 Astrazeneca Ab Eljárás a bazofil-szint csökkentésére
RU2383345C1 (ru) * 2008-08-07 2010-03-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") Способ лечения больных бронхиальной астмой
TWI732259B (zh) * 2010-12-16 2021-07-01 美商建南德克公司 關於th2抑制作用之診斷及治療
CN102544908B (zh) 2010-12-17 2016-01-06 富士康(昆山)电脑接插件有限公司 电连接器组件及插头连接器
EP2710370A4 (en) 2011-05-18 2015-01-07 Medimmune Llc METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS
HK1201440A1 (en) 2011-11-01 2015-09-04 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma
CA2918105C (en) * 2013-08-12 2023-02-28 Medimmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab
CN111617244A (zh) * 2013-08-12 2020-09-04 阿斯特拉捷利康股份公司 使用贝那利珠单抗改善哮喘症状的方法

Also Published As

Publication number Publication date
SMT202100152T1 (it) 2021-05-07
RU2016108809A (ru) 2017-09-18
WO2015023507A3 (en) 2015-04-09
US9441046B2 (en) 2016-09-13
EP4636400A2 (en) 2025-10-22
CN111588849A (zh) 2020-08-28
CY1122033T1 (el) 2020-10-14
PL3520811T3 (pl) 2021-08-02
CY1124399T1 (el) 2022-07-22
LT3520811T (lt) 2021-03-25
HK1225300A1 (en) 2017-09-08
CA2917603A1 (en) 2015-02-19
RS58711B1 (sr) 2019-06-28
KR102337599B1 (ko) 2021-12-10
EP4579236A2 (en) 2025-07-02
RU2016108809A3 (https=) 2018-06-18
SG11201600483QA (en) 2016-02-26
JP2020125304A (ja) 2020-08-20
TR201907907T4 (tr) 2019-06-21
HRP20190920T1 (hr) 2019-07-12
SMT201900311T1 (it) 2019-07-11
EP3875487A1 (en) 2021-09-08
JP2022120010A (ja) 2022-08-17
AU2014306959A1 (en) 2016-02-04
HUE043497T2 (hu) 2019-08-28
DK3033104T3 (da) 2019-06-17
RS61565B1 (sr) 2021-04-29
EP3033104A2 (en) 2016-06-22
CA2917603C (en) 2023-05-16
HRP20210406T1 (hr) 2021-04-30
EP3033104B1 (en) 2019-04-03
ES2866426T3 (es) 2021-10-19
JP6746496B2 (ja) 2020-08-26
JP2024129140A (ja) 2024-09-26
EP4636400A3 (en) 2025-12-24
MX2021003826A (es) 2021-05-27
SI3520811T1 (sl) 2021-04-30
SI3033104T1 (sl) 2019-06-28
DK3520811T3 (da) 2021-03-22
EP3033104A4 (en) 2017-03-22
ES2733602T3 (es) 2019-12-02
WO2015023507A2 (en) 2015-02-19
EP3520811A1 (en) 2019-08-07
EP4579236A3 (en) 2025-09-17
LT3033104T (lt) 2019-06-25
MX381102B (es) 2025-03-12
JP2016527325A (ja) 2016-09-08
WO2015023507A8 (en) 2015-09-24
PT3033104T (pt) 2019-06-27
PT3520811T (pt) 2021-03-15
AU2014306959B2 (en) 2019-11-21
RU2703568C2 (ru) 2019-10-21
HUE053627T2 (hu) 2021-07-28
KR20160043049A (ko) 2016-04-20
CN105451769A (zh) 2016-03-30
MX2016001384A (es) 2016-08-03
AU2020201277A1 (en) 2020-03-12
BR112016002317A2 (pt) 2017-12-12
US20150044203A1 (en) 2015-02-12
EP3520811B1 (en) 2020-12-30
BR112016002317A8 (pt) 2018-06-12
PL3033104T3 (pl) 2019-09-30
ME03403B (me) 2020-01-20

Similar Documents

Publication Publication Date Title
HK1222559A1 (zh) 使用貝那利珠單抗增加哮喘患者用力呼氣量的方法
US9441037B2 (en) Methods for reducing exacerbation rates of asthma using benralizumab
HK1225302A1 (en) Methods for reducing exacerbation rates of asthma using benralizumab
HK1221647A1 (zh) 使用貝那利珠單抗改善哮喘症狀的方法
HK40035227A (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK40129473A (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK40058739A (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
RU2840902C2 (ru) Способы нормализации симптомов астмы с применением бенрализумаба
HK40012636B (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK40012636A (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK1225300B (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK40035226A (en) Methods for reducing exacerbation rates of asthma using benralizumab
HK40035228A (en) Methods for improving asthma symptoms using benralizumab